Inclusion Criteria:

- Unresectable stage III and stage IV M1a/M1b/M1c melanoma including patients with
uveal melanoma

- Age ≥ 18 years

- Life expectancy ≥ 4 months

- ECOG performance status 0-2

- HLA-A2 positive

- gp100 expression > 6% in primary lesion or metastasis

- At least 28 days from prior treatment (including adjuvant interferon) except in cases
of a BRAF inhibitor (such as vemurafenib); concurrent treatment with a BRAF inhibitor
is permitted

- Required initial laboratory values (submitted within 14 days prior to registration):

- WBC >3,000/mm3

- Hg ≥ 9.0 gm/dl Platelets >75,000/mm3 Serum Bilirubin < 2.0 mg/dl Serum
Creatinine < 2.0 mg/dl

- Sexually active women of childbearing potential must use effective birth control
during the trial and for at least two months following the trial, and sexually active
men must be willing to avoid fathering a new child while receiving therapy.

Exclusion Criteria:

- Prior treatment with more than one line of cytotoxic chemotherapy; prior treatment
with one line of cytotoxic chemotherapy is permitted. Prior treatment with targeted
therapy (such as ipilumumab, and BRAF inhibitor) is permitted

- Active untreated CNS metastasis

- Active infection

- Prior malignancy (except non-melanoma skin cancer) within 3 years

- Pregnant or nursing

- Concurrent treatment with corticosteroids; local (inhaled or topical) steroids are
permitted.

- Inability to provide adequate informed consent

- Known allergy to eggs

- Prior history or uveitis or autoimmune inflammatory eye disease.

- Known positivity for hepatitis BsAg, hepatitis C antibody, or HIV antibody.